XML 57 R43.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaborative Agreements (Details) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Dec. 29, 2017 | Aug. 07, 2015 USD ($) product | Dec. 31, 2017 USD ($) | Feb. 28, 2017 USD ($) | Sep. 30, 2015 USD ($) | Apr. 30, 2015 USD ($) | Sep. 30, 2013 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Sep. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Mar. 31, 2016 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  | $ 7,409,214 | $ 351,272 | $ 16,358,316 | $ 4,288,586 | $ 476,586 | $ 2,327,316 | $ 1,889,988 | $ 1,796,857 | $ 28,407,388 | $ 6,490,747 | $ 26,876,533
Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
MedImmune | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 27,500,000 |  |  | $ 27,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional revenue to be achieved |  | $ 700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional products | product |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  | $ 7,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,300,000 | 1,500,000 |
Deferred revenue |  |  | 1,100,000 |  |  |  |  |  | 1,100,000 |  |  |  | 13,700,000 |  |  |  | 1,100,000 | 13,700,000 |
Accounts receivable |  |  | 1,700,000 |  |  |  |  |  | 1,700,000 |  |  |  | 1,200,000 |  |  |  | 1,700,000 | 1,200,000 |
Roche | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,100,000 | 4,900,000 |
Accounts receivable |  |  | 0 |  |  |  |  |  | 0 |  |  |  | 2,400,000 |  |  |  | 0 | 2,400,000 |
Full payment |  |  |  | $ 8,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DARPA | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  | 149,000 |  |  |  |  |  | 149,000 |  |  |  | 1,200,000 |  |  |  | 149,000 | 1,200,000 |
Accounts receivable |  |  | $ 4,100,000 |  |  |  |  |  | $ 4,100,000 |  |  |  | $ 9,200,000 |  |  |  | 4,100,000 | 9,200,000 |
Term |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |
Base award |  |  |  |  |  | $ 19,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Previously deferred revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 9,800,000 | $ 22,400,000 |
Option award |  |  |  |  |  | 24,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Second option award |  |  |  |  |  | $ 11,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |
ApolloBio | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Territory expansion option period | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
INO-3112 | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
INO 5150 | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  | 8,400,000 |  |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | License To Research Collaboration Products | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions |  | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | Option Right | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |
Nonsoftware License Arrangement | Joint Steering Committee Obligation | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, additions |  |  |  |  |  |  | $ 155,000 |  |  |  |  |  |  |  |  |  |  |  |
Scenario, Forecast | ApolloBio | Collaborative Arrangement, Product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  | $ 23,000,000 |  |  |  |  |  |  |  |  |  |  |
Additional revenue to be achieved |  |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Duration for upfront payment to be made following date of approval of collaborative agreement |  |  |  |  |  |  |  | 3 days |  |  |  |  |  |  |  |  |  |  |
Obligation period to pay royalties |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |  |  |

X
- Definition Collaboration Agreement, Additional Revenue To Be Achieved + References No definition available. + Details
Name: | ino_CollaborationAgreementAdditionalRevenueToBeAchieved
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreement, Royalty Period + References No definition available. + Details
Name: | ino_CollaborationAgreementRoyaltyPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Territory Expansion Option Period + References No definition available. + Details
Name: | ino_CollaborationAgreementTerritoryExpansionOptionPeriod
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Base Award + References No definition available. + Details
Name: | ino_CollaborativeAgreementBaseAward
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Option Award + References No definition available. + Details
Name: | ino_CollaborativeAgreementOptionAward
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Proceeds From Contract Termination + References No definition available. + Details
Name: | ino_CollaborativeAgreementProceedsFromContractTermination
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Second Option Award + References No definition available. + Details
Name: | ino_CollaborativeAgreementSecondOptionAward
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreements, Upfront Payment Received + References No definition available. + Details
Name: | ino_CollaborativeAgreementsUpfrontPaymentReceived
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Term + References No definition available. + Details
Name: | ino_CollaborativeArrangementTerm
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Duration for Upfront Payment to be Made Following Date of Approval of Collaborative Agreement + References No definition available. + Details
Name: | ino_DurationforUpfrontPaymenttobeMadeFollowingDateofApprovalofCollaborativeAgreement
Namespace Prefix: | ino_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Additional Products + References No definition available. + Details
Name: | ino_NumberOfAdditionalProducts
Namespace Prefix: | ino_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Under Collaborative Research and Development Arrangements + References No definition available. + Details
Name: | ino_RevenueUnderCollaborativeResearchandDevelopmentArrangements
Namespace Prefix: | ino_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(9)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_MedImmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_HoffmanLaRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=ino_ApolloBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_INO3112Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_INO5150Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_NonsoftwareLicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_LicenseToResearchCollaborationProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_OptionRightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=ino_JointSteeringCommitteeObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |